Stock Screener App

무료 -

3.275

1.36% -0.045

시간 외 거래: 3.30 0.025 +0.76%

Ovid Therapeutics Inc (OVID)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스

Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

FY2024 Earnings Forecast for Ovid Therapeutics Inc. (NASDAQ:OVID) Issued By Wedbush - MarketBeat

Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasted to Post Q2 2024 Earnings of ($0.22) Per Share - Defense World

Ovid Therapeutics Inc. (NASDAQ:OVID) Expected to Post Q1 2025 Earnings of ($0.24) Per Share - Defense World

Ovid Therapeutics Inc. (NASDAQ:OVID) to Post Q1 2025 Earnings of ($0.24) Per Share, Wedbush Forecasts - MarketBeat

Ovid Therapeutics stock holds Outperform on trial progress - Investing.com

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results - GlobeNewswire

Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research

Zacks Investment Research

Ovid Therapeutics to Present at the H.C. Wainwright 2nd - GlobeNewswire

Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $8.08 - Defense World

Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates

Zacks Investment Research

Ovid Therapeutics (NASDAQ:OVID) PT Lowered to $3.50 at Citigroup - Defense World

Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics

Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics - Ovid Therapeutics (NASDAQ:OVID) - Benzinga

Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasted to Earn Q1 2024 Earnings of ($0.22) Per Share - Defense World

B. Riley Comments on Ovid Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:OVID) - MarketBeat

B. Riley Begins Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat

HC Wainwright Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth - Yahoo Finance

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024 - Seeking Alpha

Marinus Pharmaceuticals Stands Firm in Patent Dispute Over Key Epilepsy Treatment - MyChesCo

Marinus Pharmaceuticals defends key patent against Ovid challenge - Investing.com

Ovid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock Buying - Yahoo Finance

Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - Markets Insider

Markets Insider

Institutional investors may overlook Ovid Therapeutics Inc.'s (NASDAQ:OVID) recent US$28m market cap drop as long-term gains remain positive - Simply Wall St

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire

Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon ... - Yahoo Finance

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire Inc.

Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress

Zacks Investment Research

Scrip Awards Lifetime Achievement Winner Jeremy Levin Urges Pharma To Put Humanity First :: Scrip - Scrip

Ovid Therapeutics Inc (OVID) Reports Q3 2023 Financial Results - Yahoo Finance

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat ... - Yahoo Finance

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire

Final trial data support Ovid's decision to stop OV101 program in... - Angelman Syndrome News

Angelman Syndrome News

Madison Avenue Partners, LP Boosts Stake in Ovid Therapeutics Inc - Yahoo Finance

Jeremy Levin - Fierce healthcare

Fierce healthcare

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates - GlobeNewswire

Ovid snaps up Rock2 inhibitor from Sam Waksal-led biotech, continuing climb through neurological terrain - Fierce Biotech

DelveInsight Evaluates a Robust Epilepsy Pipeline as 70+ Influential Pharma Players to Set Foot in the Domain - PR Newswire

In Support of FDA's Authority to Regulate Medicines - TimmermanReport.com - Timmerman Report

Timmerman Report

Gensaic enters into collaboration to develop phage-derived gene therapies for central nervous system - EurekAlert

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results - GlobeNewswire

AstraZeneca and Ovid Therapeutics Team Up Against Epilepsy - BioSpace

UTHR: 3 Undervalued Biotech Stocks to Watch in July - StockNews.com

$76.97

4.27%

$151.22

2.59%

$29.65

1.89%

$171.03

3.73%

$376.60

0.10%

$92.98

0.85%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기